Gao, Guozhen http://orcid.org/0000-0002-9510-1474
Hausmann, Simone http://orcid.org/0000-0001-9577-4225
Flores, Natasha M.
Benitez, Ana Morales
Shen, Jianjun
Yang, Xiaojie http://orcid.org/0000-0002-4242-2127
Person, Maria D. http://orcid.org/0000-0001-8161-9339
Gayatri, Sitaram http://orcid.org/0000-0002-0773-6278
Cheng, Donghang http://orcid.org/0000-0001-7356-450X
Lu, Yue
Liu, Bin
Mazur, Pawel K. http://orcid.org/0000-0002-5820-8344
Bedford, Mark T. http://orcid.org/0000-0002-8899-1050
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM126421)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA236118, R01CA266280)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 26 April 2022
Accepted: 4 January 2023
First Online: 23 January 2023
Competing interests
: Pawel K. Mazur is a scientific co-founder, consultant and stockholder of Amplified Medicines, Inc. and Ikena Oncology, Inc. Mark T. Bedford is the co-founder of EpiCypher. The remaining authors declare no competing interests.